FDA Approves DIPYRIDAMOLE — Hikma Pharmaceuticals USA Inc.

# FDA Approves Hikma Pharmaceuticals' Intravenous Dipyridamole Hikma Pharmaceuticals USA Inc. received FDA approval for its intravenous dipyridamole formulation, expanding the company's cardiovascular portfolio and positioning it to capture market share in the diagnostic stress testing and thromboembolism prevention segments. The approval of this generic formulation enables Hikma to offer a cost-effective alternative to branded dipyridamole products, potentially strengthening its competitive position in hospital and clinical settings.